Morgan Stanley Nu Cana PLC Transaction History

Morgan Stanley

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Oct 17, 2024	BUY	$0.26 - $0.42 $1,404 - $2,268	5,400 New	5,400 $1,000
Q1 2024 Aug 16, 2024	BUY	$0.26 - $0.42 $1,404 - $2,268	5,400 New	5,400 $1,000
Q1 2024 May 15, 2024	BUY	$0.26 - $0.42 $1,404 - $2,268	5,400 New	5,400 $1,000
Q4 2022 Feb 14, 2023	SELL	$0.66 - $27.41 $15,708 - $652,358	-23,800 Reduced 62.56%	14,246 $9,000
Q3 2022 Nov 14, 2022	BUY	$0.62 - $26.13 $23,424 - $987,217	37,781 Added 14256.98%	38,046 $40,000
Q2 2022 Oct 27, 2022	SELL	$0.59 - $1.06 $24 - $44	-42 Reduced 13.68%	265 $0
Q2 2022 Aug 15, 2022	SELL	$0.59 - $1.06 $24 - $44	-42 Reduced 13.68%	265 $0
Q1 2022 Oct 27, 2022	BUY	$0.74 - $3.27 $31 - $137	42 Added 15.85%	307 $0
Q1 2022 May 13, 2022	SELL	$0.74 - $3.27 $3,872 - $17,111	-5,233 Reduced 94.46%	307 $0
Q4 2021 Feb 14, 2022	SELL	$2.02 - $2.9 $15,457 - $22,190	-7,652 Reduced 58.0%	5,540 $13,000
Q3 2021 Nov 15, 2021	BUY	$1.95 - $2.85 $25,724 - $37,597	13,192 New	13,192 $34,000

3.33M

Ticker NCNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,196,000
Market Cap $66.3M
Description
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients ...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.